LB 100

Drug Profile

LB 100

Alternative Names: LB-1; LB-100

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer INSERM; Lixte Biotechnology Holdings
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphoprotein phosphatase inhibitors; Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Depressive disorders; Glioblastoma; Haematological disorders
  • Research Ischaemia

Most Recent Events

  • 30 Jun 2017 LB 100 is still in early research stage for Ischaemia in USA (Lixte pipeline, June 2017)
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-100 and LB-200 series compounds for the prevention and treatment of Neurodegenerative disorders in USA and Australia
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-100 in combination with anti-cancer agents in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top